Profile data is unavailable for this security.
About the company
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
- Revenue in USD (TTM)52.29m
- Net income in USD-134.84m
- Incorporated1995
- Employees405.00
- LocationSangamo Therapeutics Inc501 Canal Blvd.RICHMOND 94084United StatesUSA
- Phone+1 (510) 970-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.sangamo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics Inc | 0.00 | -35.46m | 369.65m | 31.00 | -- | 1.76 | -- | -- | -1.39 | -1.39 | 0.00 | 8.17 | 0.00 | -- | -- | 0.00 | -19.97 | -- | -20.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 217.95m | -651.19m | 378.79m | 1.22k | -- | 0.4384 | -- | 1.74 | -12.90 | -12.90 | 4.29 | 15.03 | 0.1243 | -- | 5.01 | 178,941.70 | -37.13 | -- | -40.39 | -- | 80.94 | -- | -298.78 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| ProQR Therapeutics NV | 22.33m | -25.07m | 382.31m | 157.00 | -- | 11.62 | -- | 17.12 | -0.3075 | -0.3075 | 0.2738 | 0.3106 | 0.1713 | -- | -- | 142,198.80 | -19.24 | -35.51 | -26.22 | -40.51 | -- | -- | -112.31 | -926.31 | -- | -- | 0.4105 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Verve Therapeutics Inc | 24.40m | -197.03m | 389.45m | 255.00 | -- | 0.7656 | -- | 15.96 | -2.46 | -2.46 | 0.3033 | 6.01 | 0.0382 | -- | 8.45 | 95,670.59 | -30.87 | -- | -32.86 | -- | -- | -- | -807.62 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Tango Therapeutics Inc | 43.38m | -123.40m | 389.93m | 140.00 | -- | 1.70 | -- | 8.99 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -64.77m | 391.13m | 42.00 | -- | 1.97 | -- | -- | -1.15 | -1.15 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -40.11 | -42.22 | -43.16 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Akebia Therapeutics Inc | 169.88m | -45.99m | 397.09m | 167.00 | -- | -- | -- | 2.34 | -0.2207 | -0.2207 | 0.8338 | -0.2383 | 0.7684 | 1.33 | 6.20 | 1,017,240.00 | -20.80 | -37.42 | -31.00 | -56.00 | 84.79 | 69.13 | -27.07 | -82.25 | 1.21 | -2.52 | -- | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Sangamo Therapeutics Inc | 52.29m | -134.84m | 408.11m | 405.00 | -- | 10.45 | -- | 7.80 | -0.7079 | -0.7079 | 0.2696 | 0.1876 | 0.316 | -- | 8.98 | 129,113.60 | -81.48 | -26.09 | -112.69 | -31.04 | -- | -- | -257.86 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| 4D Molecular Therapeutics Inc | 18.00k | -143.48m | 415.24m | 201.00 | -- | 0.7513 | -- | 23,068.72 | -2.76 | -2.76 | 0.0004 | 10.63 | 0.00004 | -- | -- | 122.45 | -29.72 | -32.67 | -31.26 | -34.90 | -- | -- | -797,111.10 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Zenas Biopharma Inc | 0.00 | -128.97m | 415.43m | 115.00 | -- | 1.21 | -- | -- | -3.19 | -3.19 | 0.00 | 8.60 | 0.00 | -- | -- | 0.00 | -52.94 | -- | -60.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 422.40m | 38.00 | -- | 528.14 | -- | 8.81 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 429.18m | 116.00 | -- | -- | -- | 16.82 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| ACELYRIN Inc | 0.00 | -264.41m | 432.17m | 130.00 | -- | 0.8192 | -- | -- | -2.68 | -2.68 | 0.00 | 5.29 | 0.00 | -- | -- | 0.00 | -37.27 | -- | -41.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Allogene Therapeutics Inc | 43.00k | -283.43m | 442.41m | 232.00 | -- | 0.9532 | -- | 10,288.56 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 446.78m | 52.00 | -- | 5.03 | -- | 45.06 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Omeros Corp | 0.00 | -185.38m | 447.93m | 198.00 | -- | -- | -- | -- | -3.14 | -2.30 | 0.00 | -2.66 | 0.00 | -- | -- | 0.00 | -45.98 | -55.51 | -61.42 | -70.10 | -- | -- | -- | -- | -- | -6.07 | 1.59 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Data as of Nov 22 2024. Currency figures normalised to Sangamo Therapeutics Inc's reporting currency: US Dollar USD
22.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wasatch Advisors LPas of 30 Sep 2024 | 19.44m | 9.34% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 9.54m | 4.58% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 4.85m | 2.33% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.99m | 1.44% |
| Marshall Wace LLPas of 30 Sep 2024 | 2.35m | 1.13% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.14m | 1.03% |
| Millennium Management LLCas of 30 Sep 2024 | 1.91m | 0.92% |
| Jacobs Levy Equity Management, Inc.as of 30 Sep 2024 | 1.47m | 0.71% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 1.10m | 0.53% |
| Hightower Advisors LLCas of 30 Sep 2024 | 793.08k | 0.38% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
